Association of lipoprotein-associated phospholipase A2 mass with asymptomatic cerebral artery stenosis

Youxin Wang1 | Bin Zhou2 | Pingan Zhou3 | Yan Yao4 | Qinghua Cui5 | Yingping Liu6 | Jichun Yang7 | Shouling Wu8 | Xingquan Zhao9,10,11,12 | Yong Zhou13

1Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing, China
2Department of Neurosurgery, Baotou Eighth Hospital, Baotou, China
3Department of Ultrasound, Yan'an University Affiliated Hospital, Yan'an, China
4Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
5Department of Biomedical Informatics, Center for Noncoding RNA Medicine, MOE Key Laboratory of Cardiovascular Sciences, School of Basic Medical Sciences, Peking University, Beijing, China
6Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
7Pathophysiology, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Science of the Ministry of Education Center for Non-coding RNA Medicine, Peking University Health Science Center, Beijing, China
8Department of Cardiology, Kaikun Hospital, North China University of Science and Technology, Tangshan, China
9Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
10China National Clinical Research Center for Neurological Diseases, Beijing, China
11Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
12Beijing Municipal Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
13Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China

Abstract
Cerebral artery stenosis (CAS) is the most important causes of ischaemic stroke. Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays 2 diverse roles in atherosclerosis (pro-inflammatory and anti-inflammatory), and the association between Lp-PLA2 mass and cardiovascular or cerebrovascular events is inconsistent among previous studies. A cross-sectional study including 2012 North Chinese adults aged ≥40 years was performed in 2010-2011 to investigate whether Lp-PLA2 mass is associated with asymptomatic cerebral artery stenosis (ACAS). Serum Lp-PLA2 mass was determined by enzyme-linked immunosorbent assay (ELISA). All participants underwent transcranial Doppler (TCD) and bilateral carotid duplex ultrasound to evaluate intracranial artery stenosis (ICAS) and extracranial arterial stenosis (ECAS). The median serum Lp-PLA2 mass of the participants was 140.74 ng/mL (interquartile range: 131.79-158.07 ng/mL). The adjusted odds ratio (OR) when comparing the 4th quartile to the 1st quartile of Lp-PLA2 was 1.98 (95% confidence interval: 1.42-2.78), 1.79 (95% CI: 1.08-2.94) and 1.87 (95% CI: 1.28-2.73) for the occurrence of ACAS, asymptomatic ECAS and asymptomatic ICAS, respectively.

Youxin Wang and Bin Zhou equally contributed to this study.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

J Cell Mol Med. 2018;22:2329–2336.
after controlling for vascular risk factors. These independently significant associations remained statistically significant in the male or elderly subgroups, but not in females or middle-aged participants. Lp-PLA2 mass is positively correlated with subclinical atherosclerosis determined by ACAS, ICAS and ECAS in North Chinese, particularly in male and older participants, suggesting that serum Lp-PLA2 mass might be potential biomarker for the detection of ACAS in the adults.

**KEYWORDS**

asymptomatic cerebral artery stenosis, cross-sectional study, lipoprotein-associated phospholipase A2 (Lp-PLA2), the Asymptomatic Polyvascular Abnormalities in Community

---

**1 | INTRODUCTION**

Cerebral artery stenosis (CAS) is the most common pathogen of ischaemic stroke worldwide.\(^1\) Without treatment, cerebral artery stenosis can dramatically increase the risk of transient ischaemic attacks (TIAs), ministrokes or strokes. In China, stroke is responsible for approximately 20% of all causes of death.\(^2\) The prevalence of intracranial atherosclerotic disease in China is higher than that in other populations, being responsible of as far as one-third of strokes.\(^3\) Currently, the diagnosis of ischaemic stroke (IS) is mainly based on the experience of clinicians and brain imaging results. However, many patients with a suspected stroke are not assessed in a timely manner (within the first few hours after the event). Thus, establishing an accurate and quick screen procedure in patients with suspected acute ischaemic stroke is very important.\(^4\) Identification of serum biomarkers is one of the primary strategies used to identify populations at risk of ischaemic stroke. Among these strategies, lipoprotein-associated phospholipase A2 (Lp-PLA2) has been identified as a promising soluble blood-based biomarker.\(^5\)

Lp-PLA2 is a type of serine lipase, majority of which bound to low-density lipoproteins (LDL) and less of which bound to high-density lipoprotein (HDL) or very low-density lipoprotein (VLDL).\(^6\) Paradoxically, the role of Lp-PLA2 in the progression of atherosclerosis is controversial.\(^7,9\) As a well-established pro-inflammatory factor, Lp-PLA2 is extensively involved in the progression of atherosclerosis, including plaque formation, development and rupture.\(^10\) A high level of Lp-PLA2 has been proved to be a positive risk factor for cardiovascular and cerebrovascular events in multiple large-scale population studies.\(^5,11-15\) The Northern Manhattan Study has reported a correlation between Lp-PLA2 mass and increased risk of first atherosclerotic stroke among non-Hispanic White participants during an 11-year follow-up (adjusted hazard ratio [HR], 1.55; 95% CI, 1.17-2.04).\(^4\) In a pooling analysis of 32 prospective studies, Lp-PLA2 mass was found to be associated with risk of coronary heart disease and vascular death, with adjusted relative risk (RR) of 1.11 (1.07-1.16) for coronary heart disease, 1.14 (1.02-1.27) for ischaemic stroke, 1.13 (1.05-1.22) for vascular mortality and 1.10 (1.03-1.18) for non-vascular mortality.\(^11\) In contrast, some studies demonstrated a decrease in Lp-PLA2 enzymatic activity in patients with acute myocardial infarction and no correlation with premature coronary atherosclerosis.\(^16,17\) therefore, the underlying mechanism remains unclear.

Lp-PLA2 is well recognized as a potential biomarker for the vascular inflammation and formation of rupture-prone plaques.\(^18\) Lp-PLA2 is considered to predict the risk of not only first-ever but also recurrent strokes,\(^19-22\) but it does not correlate with acute cerebrovascular ischaemic diseases.\(^23\) This discrepancy might be due to the heterozygous phenotypes of stroke and the paradoxical roles of Lp-PLA2 in the inflammation. Lp-PLA2 mass is significantly associated with isolated ICAS and concurrent extra-intracranial stenosis but not related to isolated ECAS, in a stroke-free hypertension population from North China.\(^24\) In this study, we examined asymptomatic cerebral artery stenosis (ACAS), an intermediate indicator that can remain silent for a long period before the occurrence of ischaemic stroke,\(^25\) and suggested that aberrant increase in Lp-PLA2 mass might be associated with ACAS in a vascular disease-free population. The objective of this study was to investigate the association between serum levels of Lp-PLA2 with ACAS and ICAS in a Chinese cohort, with the aim of identifying useful and novel biomarkers for the prediction of stroke at an early stage.

**2 | METHODS**

**2.1 | Study design and population**

The participants and design of the Asymptomatic Polyvascular Abnormalities in Community (APAC) study can be referred to your previously description.\(^26\) The APAC study included a random sample of 5440 participants aged ≥40 years. The participants were selected from the baseline population from the Kailuan Study and included 101 510 current employees and retirees from the Kailuan (Group) Co. Ltd.\(^26\) The APAC study protocol has been previously reported in detail.\(^26\) Among the 5440 participants, 2012 with complete demographic and blood sample information were randomly selected to investigate the association between serum levels of Lp-PLA2 and ACAS.

**2.2 | Measurement of Lp-PLA2**

The correlation between Lp-PLA2 mass and Lp-PLA2 activity was about 0.50.\(^11\) In addition, the Lp-PLA2 mass and Lp-PLA2 activity
had similar predictive power for the cardiac death\textsuperscript{27} and stroke.\textsuperscript{28} Therefore, we measured Lp-PLA2 mass only.

Venous bloods were collected in the fasting condition, and EDTA was used as an anticoagulant. The blood samples were centrifuged for 5 minutes at 500 × g, within 2 hours of field collection, and serum was separated and placed in microcentrifuge tubes. Blood samples had unified number for each participant and were stored at −80°C. To reduce the inter assay error and measurement error, the Lp-PLA2 mass for all participants was assessed simultaneously by a professional technician using the human Lp-PLA2 enzyme immunoassay kit (CUSABIO, Wuhan, China) at Beijing Tiantan Hospital, Capital Medical University, Beijing, China, according to the manufacturer’s instructions.

2.3 | Assessment of cerebral artery stenosis

Intracranial artery stenosis (ICAS) was assessed through the use of a transcranial Doppler (TCD) by 2 independent experienced neurologists using portable machines (EME, Companion, Nicolet), according to standardized protocol and diagnosis criteria.\textsuperscript{26} Artery stenosis was defined by the peak systolic flow velocity as follows: >140 cm per second for the middle cerebral artery, or >120 cm per second for the anterior cerebral artery, or >100 cm per second for the posterior cerebral artery and vertebral-basilar artery or >120 cm per second for the ICAS. Except for velocity criteria, the presence of turbulence or background noise, and whether the abnormal velocity was considered to be segmental.

Every participant also underwent a bilateral carotid duplex ultrasound (Philips iU-22 ultrasound system, Philips Medical Systems, Bothell, WA, USA) to assess extracranial arterial stenosis (ECAS). Bilateral ECAS arteries included common carotid arteries, carotid bifurcation, the internal carotid artery and the external carotid artery. All participants were examined in the supine position with the head turned to the contralateral side. Both sides of the carotid arteries were evaluated for the presence of ECAS (≥50%), which was graded based on recommendations from the Society of Radiologists in Ultrasound Consensus Conference.\textsuperscript{29} ACAS was defined by the presence of at least one of ECAS or ICAS.

2.4 | Covariates

Demographic variables including age, sex and history of hypertension, diabetes mellitus and dyslipidaemia were collected via questionnaires. All participants were divided into 2 groups based on their ages: 40–59 years and ≥60 years. Information regarding disease history, including hypertension, diabetes mellitus or hyperlipidaemia, as well as smoking history, which was classified as “yes” or “no” was also collected via questionnaires. Weights (accurate to 0.1 kg) and heights (accurate to 0.1 cm) were measured during the physical examination, and body mass index (BMI) values were calculated. Hypertension was defined as the presence of hypertension history, use of antihypertensive medication, a systolic blood pressure (SBP) ≥140 mm Hg or a diastolic blood pressure (DBP) ≥90 mm Hg. Diabetes mellitus was defined by self-reported history, current use of insulin or oral hypoglycaemic agents, or a fasting blood glucose level ≥7.0 mmol/L (126 mg/dL). Dyslipidaemia was defined as a self-reported history, current use of cholesterol-lowering medication, total cholesterol (TC) level ≥220 mg/dL or triglycerides (TG) ≥150 mg/dL or low-density lipoprotein cholesterol (LDL-C) ≥160 mg/dL. C-Reactive protein (CRP) was measured by high-sensitivity nephelometry assay (Cias Latex CRP-H; Kanto Chemical Co. Inc, Tokyo, Japan). CRP concentrations were categorized into 2 groups according to the guideline.\textsuperscript{30} All blood examinations were performed at the central laboratory of Kailuan Hospital.

2.5 | Statistical analyses

Continuous variables are presented as the mean ± standard deviation or median together with interquartile range, whereas categorical variables are presented number together with percentages. Continuous variables were compared using analysis of variance (ANOVA) for normally distributed variables and nonparametric approach for skewed distributed variables. The intergroup differences in categorical variables were compared using chi-square tests. We used logistic regression to determine the association between the Lp-PLA2 mass and cerebral artery stenosis risk and represented as odds ratio (OR) and 95% confidence interval (CI). Known confounding factors including age, sex, BMI, current smoker, alcohol use, hypertension, diabetes mellitus and dyslipidaemia were controlled in the logistic regression. All statistical tests were 2-sided, and \( P < .05 \) was considered to be statistically significant. All analyses were performed with SAS (version 9.1; SAS Institute, Cary, NC, USA) software.

2.6 | Ethics statement

This study was approved by the Ethics Committees of Beijing Tian- tan Hospital, Capital Medical University. All participants signed informed consent forms before the participation in this study.

3 | RESULTS

This study consisted of 1482 males and 530 females with a mean age of \( 60.5 ± 11.7 \) years. The median Lp-PLA2 mass was 141.74 ng/mL (interquartile range, 131.79–158.07 ng/mL), which divided to 4 quartiles, 1st quartile (<131.79 ng/mL), 2nd quartile (131.79–140.74 ng/mL), 3rd quartile (140.75–158.07) and 4th quartile (>158.07 ng/mL). ACAS was detected in 479 (23.6%) participants (363 were ICAS and 191 were ECAS).

We summarized the baseline characteristics of all participants in Table 1. In this stroke-free cohort, participants with ACAS were older (60.45 vs 59.16 years) and included more males than females (79.75% vs 20.25%). Moreover, participants in the ACAS group were more likely than the non-ACAS group to suffer from hypertension and diabetes mellitus. The biochemical indicators of Lp-PLA2, glucose (GLU), total cholesterol (CHOL), C-reactive protein (CRP) and
homocysteine (HCY) in the ACAS group were significant higher than those in the non-ACAS group (all \( P < .05 \)).

The association between artery stenosis and Lp-PLA2 mass was summarized in Table 2. Compared to the participants in the 1st quartile of Lp-PLA2 mass, there was an increased risk of ACAS among participants in the 2nd quartile (OR, 1.47; 95% CI, 1.05-2.05), 3rd quartile (OR, 1.64; 95% CI, 1.18-2.29) and 4th quartile (OR, 1.98; 95% CI, 1.42-2.78), after controlling for sex, age, smoking, alcohol, exercise, hypertension, hyperlipidaemia, diabetes and BMI using Lp-PLA2 mass quartiles. The association between Lp-PLA2 mass and ACAS was similar in the 2 stenosis subgroups. There was a trend towards an increased risk of asymptomatic ECAS in comparison with that of the 1st quartile, 2nd quartile (OR, 1.50; 95% CI, 1.02-2.19), 3rd quartile (OR, 1.69; 95% CI, 1.15-2.43) and 4th quartile (OR, 1.87; 95% CI, 1.28-2.73), after controlling for age, sex, hypertension, diabetes mellitus, dyslipidaemia, smoking, alcohol and BMI. When CRP was further adjusted, these associations remain statistically significant (Table 2), indicating that the associations between Lp-PLA2 mass and ACAS, ECAS and ICAS was independent to CRP.

In the stratified analysis, compared to the participants in the 1st quartile of Lp-PLA2 mass, increased risk of ACAS in the 4th quartile was statistically significant in the males (OR, 2.00; 95% CI, 1.36-2.93) but not significant in females (OR, 1.75; 95% CI, 0.86-3.54), and was significant in participants aged <60 years (OR, 2.76; 95% CI, 1.66-4.57) but not significant in participants aged \( \geq 60 \) years (OR, 1.56; 95% CI, 0.96-2.55). For stratification analyses, the association remained statistically significant only in males and in the elder (aged \( \geq 60 \) years).

### Table 1: Baseline characteristics of ICAS, ECAS and ACAS groups

|                      | Non-ACAS (n = 1539) | ACAS (n = 473) | ICAS (n = 358) | ECAS (n = 186) |
|----------------------|---------------------|---------------|---------------|---------------|
| **Sociodemographic factors** |                     |               |               |               |
| Male sex, n (%)      | 1105 (71.80)        | 377 (79.70)** | 270 (75.42)   | 170 (91.40)** |
| Age (Y)              | 57.41 (51.18, 66.45)| 63.12 (54.14, 74.78)** | 63.89 (55.04, 74.25)** | 69.72 (54.25, 78.71)** |
| Age category, n (%)  |                     |               |               |               |
| <60 y                | 918 (82.55)         | 194 (14.45)** | 140 (12.59)** | 65 (5.85)**   |
| \( \geq 60 \) y      | 621 (69.00)         | 279 (31.00)** | 218 (24.22)** | 121 (13.44)** |
| **Vascular risk factors** |                     |               |               |               |
| Hypertension, n (%)  | 821 (53.35)         | 342 (72.30)** | 279 (77.93)** | 120 (64.52)   |
| Diabetes mellitus, n (%) | 223 (14.49)       | 111 (23.47)** | 94 (26.26)**  | 42 (22.58)*   |
| Dyslipidaemia, n (%)  | 811 (52.70)         | 257 (54.33)   | 204 (56.98)   | 93 (50.00)    |
| Body mass index (kg/m\(^2\)) | 24.77 (22.72, 26.89) | 24.86 (22.85, 27.34) | 25.00 (23.11, 27.34) | 24.42 (22.15, 27.08) |
| Smoke, n (%)         | 575 (37.36)         | 192 (40.59)   | 133 (37.15)   | 89 (47.85)**  |
| Alcohol, n (%)       | 256 (16.63)         | 68 (14.38)    | 49 (17.79)    | 27 (14.52)    |
| Exercise, n (%)      | 612 (39.77)         | 202 (42.71)   | 161 (44.97)   | 82 (44.09)    |
| **Laboratory measurements** |                     |               |               |               |
| Lp-PLA2 mass (ng/mL) | 139.35 (131.19, 155.00) | 146.10 (135.18, 169.83)** | 145.91 (135.45, 171.86)** | 147.98 (135.06, 177.69)** |
| Lp-PLA2 mass category, n (%) |       |               |               |               |
| <200 ng/mL           | 1403 (77.51)        | 407 (22.49)** | 306 (16.91)** | 158 (8.73)**  |
| \( \geq 200 \) and \(< 223 \) ng/mL | 40 (70.18)       | 17 (29.82)**  | 12 (21.05)**  | 8 (14.04)**   |
| \( \geq 223 \) ng/mL | 96 (66.21)          | 49 (33.79)**  | 40 (27.59)**  | 20 (13.79)**  |
| GLU (mmol/L)         | 5.24 (4.85, 5.83)   | 5.42 (4.90, 6.50)** | 5.50 (4.95, 6.61)** | 5.40 (4.80, 6.43) |
| CHOL (mmol/L)        | 5.06 (4.43, 5.78)   | 5.19 (4.58, 5.86)* | 5.23 (4.64, 5.97)* | 5.10 (4.53, 5.10) |
| TG (mmol/L)          | 1.30 (0.93, 1.90)   | 1.32 (0.94, 1.89) | 1.33 (1.00, 1.96) | 1.21 (0.86, 1.71) |
| HDL-C (mmol/L)       | 1.56 (1.29, 1.91)   | 1.53 (1.25, 1.89) | 1.53 (1.25, 1.88) | 1.59 (1.30, 1.91) |
| LDL-C (mmol/L)       | 2.60 (2.14, 3.12)   | 2.72 (2.19, 3.18) | 2.74 (2.18, 3.19) | 2.76 (2.19, 3.19) |
| CRP (mg/L)           | 1.10 (0.56, 2.30)   | 1.40 (0.70, 3.00)** | 1.44 (0.80, 3.14)** | 1.41 (0.70, 3.40)** |
| HCY (\( \mu \)mol/L) | 14.70 (11.00, 20.70) | 16.05 (11.80, 22.72)** | 16.00 (11.60, 21.80)* | 18.15 (13.00, 24.15)** |
| UA (\( \mu \)mol/L)  | 295.00 (237.00, 358.00) | 313.00 (250.00, 366.00) | 303.50 (250.95, 370.00) | 309.00 (264.00, 362.00) |

ICAS, intracranial artery stenosis; ECAS, extracranial artery stenosis; ACAS, asymptomatic cerebral artery stenosis.

*Denotes a significance level of \( P < .05 \).

**Denotes a significance level of \( P < .01 \).
## Table 2: Association between Lp-PLA2 mass and ACAS, ECAS or ICAS

|                | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | Model 6 |
|----------------|---------|---------|---------|---------|---------|---------|
|                | Male    | Female  | Age <60 y | Age ≥ 60 y |
| ACAS           |         |         |         |         |         |         |
| Quartile 1     | 1       | 1       | 1       | 1       | 1       | 1       |
| Quartile 2     | 1.59 (1.14-2.20) | 1.47 (1.06-2.04) | 1.47 (1.05-2.05) | 1.46 (1.05-2.05) | 1.42 (0.97-2.08) | 1.55 (0.76-3.17) | 1.37 (0.90-2.10) | 1.72 (0.99-2.99) |
| Quartile 3     | 2.00 (1.45-2.75) | 1.67 (1.20-2.32) | 1.64 (1.18-2.29) | 1.63 (1.17-2.28) | 1.63 (1.11-2.37) | 1.56 (0.78-3.13) | 1.90 (1.23-2.92) | 1.65 (0.97-2.79) |
| Quartile 4     | 2.75 (2.02-3.75) | 1.99 (1.43-2.76) | 1.98 (1.42-2.78) | 1.96 (1.40-2.75) | 2.00 (1.36-2.93) | 1.75 (0.86-3.54) | 1.56 (0.96-2.55) | 2.76 (1.66-4.57) |
| ICAS           |         |         |         |         |         |         |
| Quartile 1     | 1       | 1       | 1       | 1       | 1       | 1       |
| Quartile 2     | 1.65 (1.14-2.39) | 1.52 (1.05-2.21) | 1.50 (1.02-2.19) | 1.49 (1.02-2.18) | 1.40 (0.90-2.19) | 1.72 (0.82-3.63) | 1.35 (0.82-2.21) | 1.80 (0.98-3.31) |
| Quartile 3     | 2.13 (1.49-3.05) | 1.73 (1.20-2.50) | 1.67 (1.15-2.43) | 1.66 (1.14-2.42) | 1.65 (1.06-2.56) | 1.60 (0.76-3.33) | 2.04 (1.25-3.34) | 1.60 (0.89-2.88) |
| Quartile 4     | 2.72 (1.92-3.86) | 1.88 (1.30-2.73) | 1.87 (1.28-2.73) | 1.84 (1.25-2.69) | 1.77 (1.08-2.78) | 1.92 (0.91-4.01) | 1.37 (0.76-2.45) | 2.61 (1.50-4.57) |
| ECAS           |         |         |         |         |         |         |
| Quartile 1     | 1       | 1       | 1       | 1       | 1       | 1       |
| Quartile 2     | 1.47 (0.89-2.41) | 1.32 (0.79-2.19) | 1.32 (0.79-2.19) | 1.31 (0.79-2.18) | 1.30 (0.77-2.22) | 1.39 (0.22-8.58) | 1.35 (0.69-2.64) | 1.49 (0.67-3.32) |
| Quartile 3     | 1.79 (1.10-2.90) | 1.42 (0.86-2.34) | 1.42 (0.86-2.35) | 1.40 (0.85-2.32) | 1.37 (0.81-2.32) | 1.87 (0.34-10.17) | 1.45 (0.71-2.97) | 1.70 (0.80-3.62) |
| Quartile 4     | 2.74 (1.73-4.33) | 1.79 (1.09-2.94) | 1.79 (1.08-2.94) | 1.73 (1.05-2.86) | 1.72 (1.02-2.91) | 2.04 (0.37-11.12) | 1.68 (0.79-3.58) | 2.48 (1.20-5.10) |

ACAS, asymptomatic cerebral artery stenosis; ECAS, extracranial artery stenosis; ICAS, intracranial artery stenosis. Bold OR (95% CI) indicates statistically significant.

Model 1: Unadjusted; Model 2: Adjusted for age and sex; Model 3: Adjusted for age, sex, hypertension, diabetes mellitus, dyslipidaemia, smoking, alcohol and BMI; Model 4: Adjusted for age, sex, hypertension, diabetes mellitus, dyslipidaemia, smoking, alcohol, BMI and CRP; Model 5: Adjusted for all (except sex, CRP) and stratified by age; Model 6: Adjusted for all (except age, CRP) and stratified by sex.
4 | DISCUSSION

The present study indicated that the serum Lp-PLA2 mass was elevated with ACAS. The results demonstrated that elevated Lp-PLA2 mass is independently associated with the increased risk of ACAS (either ICAS or ECAS), and the independent association is statistically significant in the male or elderly subgroups, but not significant in females or middle-aged participants. To our knowledge, this is the first attempt to investigate the association between Lp-PLA2 mass and the presence of subclinical atherosclerosis in a general and asymptomatic Chinese population, and the only study addressing the association between Lp-PLA2 mass and ACAS, ICAS or ECAS in terms of general population levels.

We found that a high Lp-PLA2 mass (eg 4th quartile) was associated with an increased risk of ACAS. Our findings were in part consistent with the findings reported in another population (stroke-free hypertensive patients), which showed that Lp-PLA2 mass was independently associated with isolated ICAS (OR, 2.30; 95% CI, 1.14-4.64) and concurrent extra-intracranial stenosis (OR, 3.93; 95% CI, 1.62-9.51) but not isolated ECAS (OR, 1.54; 95% CI, 0.68-3.48). Recently, a systematic review was performed to explore the association between Lp-PLA2 and markers of subclinical cardiovascular disease; the results showed that 3 of 6 studies favour the relationship between Lp-PLA2 and coronary artery calcification (CAC), 3 of 5 studies favour the relationship between Lp-PLA2 and carotid intima-media thickness (CIMT), and one of 2 studies favours the association between Lp-PLA2 and endothelial dysfunction. Taken together, these findings indicate a variable association of Lp-PLA2 subclinical atherosclerosis. Thus, Lp-PLA2 provides an important opportunity to appropriately classify the participants who are actually at high risk but mistakenly classified, and these findings have broad implications for future public health and clinical practice.

The present study revealed that the associations between Lp-PLA2 mass and ACAS were statistically significant in males but not in females. This finding is consistent with the results of the Dallas Heart Study, which has shown that Lp-PLA2 mass is modestly associated with CAC in males but not in females. Our finding is similar to the results of the Chinese Multiprovincial Cohort Study—Beijing Project, which showed that Lp-PLA2 activity is independently associated with the development of subclinical atherosclerosis in men but not in women. Oestrogen has been reported to be associated with the low expression or activity of Lp-PLA2, therefore, the effects of sex hormones might in part explain this sex discrepancy. Similar to other studies with the distinct gender composition (27% females in the Veterans Affairs Diabetes Trial study and 29% females in the Coronary Artery Risk Development in Young Adults study) the small proportion of females in this study cohorts (26.3%) may suggest that insufficiency in statistical power might also contribute to the non-significant association in females. Further larger, more robust studies are urged to clarify the association between ACAS risk and Lp-PLA2.

In the present study, the association between ICAS or ECAS was significant only in elderly participants (aged ≥60 years) but not in middle-aged participants (<60 years). This finding is consistent with results from a report investigating a Japanese population, but it is inconsistent with results from a study performed in Istanbul, Turkey, which showed that serum Lp-PLA2 mass is significantly increased in participants with subclinical coronary atherosclerosis compared to control patients, and Lp-PLA2 mass is positively correlated with the total number of plaques and diseased arteries in a young adult population (<45 years). The reason that Lp-PLA2 mass was not significantly associated with ACAS in middle-aged participants remains unclear; however, the lower prevalence of ACAS in middle-aged participants (14.45%) compared to that in the elderly participants (31.00%) might in part lead to the insufficient statistical power and thus make the association non-significant. Further in-depth studies are needed to explain such discrepancy.

There are several limitations to the present study. Firstly, the study relies on TCD for the diagnosis of intracranial stenoses, and not on conventional angiography, which is considered the gold standard. TCD does not collect information regarding the histopathological nature of the lesions related to vessel narrowing, and patients with non-atherosclerotic vascular pathology might have been included. Secondly, the blood samples were stored for 3-4 years at −80°C. However, it has been reported that Lp-PLA2 can be relatively stable over time when stored at −<70°C. Thirdly, the design of cross-sectional study limited the power to interpret the cause-effect association between the higher serum Lp-PLA2 mass and ACAS. Finally, most of the participants were coal workers, thus potentially limiting the ability to generalize our results to other populations.

5 | CONCLUSION

In conclusion, we found that Lp-PLA2 mass was positively correlated with subclinical atherosclerosis determined by ACAS, ICAS and ECAS, particularly in male and older participants. Considering that elevation Lp-PLA2 contributes about 2-fold risk for strokes or coronary artery disease, testing for Lp-PLA2 might be a supplementary evaluation tool to classical cardiovascular risk assessment.

ACKNOWLEDGEMENTS

This work was supported by grants from the National Natural Science Foundation of China (81673247, 81670294, 81473057, 81370083), the Joint Project of the Australian National Health and Medical Research Council and the National Natural Science Foundation of China (NHMRC APP1112767, NSFC 8156128020), Capital Health Research and Development of Special (2011-2004-03), Beijing Medical High Level Academic Leader (2014-2017) and Beijing Nova Program (Z141107001814058).

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.
REFERENCES

1. Carvalho M, Oliveira A, Azevedo E, Bastos-Leite AJ. Intracranial arterial stenosis. J Stroke Cerebrovasc Dis. 2014;23:599-609.
2. Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, Kong LZ. Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol. 2007;6:456-464.
3. Wong KS, Huang YN, Gao S, Lam WW, Chan YL, Kay R. Intracranial stenosis in Chinese patients with acute stroke. Neurology. 1998:50:812-813.
4. Katan M, Moon YP, Paik MC, Wolfert RL, Sacco RL, Elkind MS.
5. Kara H, Akinci M, Degirmenci S, et al. High-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke. Neuropsychiatr Dis Treat. 2014:10:1451-1457.
6. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413-419.
7. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor acetylhydrolases. J Biol Chem. 1997;272:17895-17898.
8. Macphee CH, Moores KE, Dhanak D, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338:479-487.
9. Macphee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol. 2001;1:121-125.
10. Miklishanskaja SV, Liakishev AA, Kukharchuk VV. Clinical role of lipoprotein-associated phospholipase A2. Kardiologija. 2012;53:59-70.
11. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010:375:1536-1544.
12. Fitzpatrick AL, Irizarry MC, Cushman M, Jenny NS, Chi GC, Koro C. Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study. Atherosclerosis. 2014;235:384-391.
13. Miklishanskaja SV, Vlasik TN, Haerts M, Ei, Liakishev AA, Kukharchuk VV. Influence of intensive hypolipidemic therapy on blood concentration of lipoprotein-associated phospholipase A2 in patients with ischemic heart disease. Kardiologija. 2013:53:4-11.
14. Holst-Albrechtsen S, Kjaergaard M, Humayun CA, Sorensen JK, Hosbond S, Nybo M. Can lipoprotein-associated phospholipase A2 be used as a predictor of long-term outcome in patients with acute coronary syndrome? Curr Cardiol Rev. 2013;9:310-315.
15. Vittos O, Toana B, Vittos A, Moldoveanu E. Lipoprotein-associated phospholipase A2 (LpPLA2): a review of its role and significance as a cardiovascular biomarker. Biomarkers. 2012:17:289-302.
16. Phillips CJ, Graham RM, Sturm MJ, Richardson M, Taylor RR. Variation in plasma platelet-activating factor degradation and serum lipids after myocardial infarction. Coron Artery Dis. 1993;4:187-193.
17. Shohet RV, Anvar A, Johnston CM, Cohen JC. Plasma platelet-activating factor acetylhydrolase activity is not associated with prematurity coronary atherosclerosis. Am J Cardiol. 1999:83:109-111.
18. Reddy KJ, Singh M, Bangir JT, Batsell RR. The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical review. J Clin Lipidol. 2009:3:85-93.
19. Delgado P, Chacón P, Penalba A, et al. Lipoprotein-associated phospholipase A2(2) activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients. Cerebrovasc Dis. 2012;33:150-158.
20. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis. 2009;27:42-50.
21. Lin J, Zheng H, Li J, et al. Association of lipoprotein-associated phospholipase A2 and early recurrence of vascular events after TIA and minor stroke. Neurology. 2015;85:1585-1591.
22. Delgado P, Chacón P, Penalba A, et al. Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting. Atherosclerosis. 2012;220:532-536.
23. Tai W, García M, Mlynash M, Kemp S, Albers GW, Olivot JM. Lipoprotein phospholipase A2 mass and activity are not associated with the diagnosis of acute brain ischemia. Cerebrovasc Dis. 2014;38:324-327.
24. Wang Y, Zhang J, Qian Y, et al. Association of Lp-PLA2 mass and asymptomatic intracranial and extracranial arterial stenosis in hypertension patients. PLoS ONE. 2015:10:e0130473.
25. Jiménez M, Dorado L, Hernández-Pérez M, et al. Ankle-brachial index in screening for asymptomatic carotid and intracranial atherosclerosis. Atherosclerosis. 2014;233:72-75.
26. Zhou Y, Li Y, Xu L, et al. Asymptomatic Polyvascular Abnormalities in Community (APAC) Study in China: objectives, design and baseline characteristics. PLoS ONE. 2014;8:e84685.
27. Rallidis LS, Tellis CC, Lekakis J, et al. Lipoprotein-associated phospholipase a(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. J Am Coll Cardiol. 2012;60:2053-2060.
28. Cuzchiara BL, Messe RS, Sapsing L, et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk stratification of patients with TIA. Stroke. 2009;40:2332-2336.
29. Grant EG, Benson CB, Moneta GL, et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis–Society of Radiologists in Ultrasound Consensus Conference. Radiology. 2003;229:340-346.
30. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
31. Younus A, Humayun CA, Ahmad R, et al. Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: a systematic review. J Lipidol. 2017;11:328-337.
32. Iribarren C, Gross MD, Darbinian JA, Jacobs DR, Sidney S, Loria CM. Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study. Clin Chem. 2008;54:1975-1981.
33. Liu J, Wang W, Qi Y, et al. Association between the lipoprotein-associated phospholipase A2 activity and the progression of subclinical atherosclerosis. J Atheroscler Thromb. 2014;21:532-542.
34. Miyaura S, Makimoto M, Byrd W, Johnston JM. The hormonal regulation of platelet-activating factor acetylhydrolase activity in plasma. Lipids. 1991:26:1015-1020.
35. Sarem AM, Moritz TE, Anderson RJ, Abraira C, Duckworth WC, Reaven PD. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2010;33:2642-2647.
36. Iribarren C, Gross MD, Darbinian JA, Jacobs DR, Sidney S, Loria CM. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol. 2005;25:216-221.
37. Ueshima H, Kadowaki T, Hisamatsu T, et al. Lipoprotein-associated phospholipase A(2) is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population. *Atherosclerosis*. 2016;246:141-147.

38. Celik O, Ozturk D, Akin F, et al. Evaluation of lipoprotein-associated phospholipase A2 and plaque burden/composition in young adults. *Coron Artery Dis*. 2015;26:266-271.

39. Oliver LK, Voskoboev N, Heser D, et al. Assessment of clinical performance without adequate analytical validation: a prescription for confusion. *Clin Biochem*. 2011;44:1247-1252.

How to cite this article: Wang Y, Zhou B, Zhou P, et al. Association of lipoprotein-associated phospholipase A2 mass with asymptomatic cerebral artery stenosis. *J. Cell. Mol. Med.* 2018;22:2329–2336. [https://doi.org/10.1111/jcmm.13521](https://doi.org/10.1111/jcmm.13521)